Spots Global Cancer Trial Database for adult grade iii meningioma

Every month we try and update this database with for adult grade iii meningioma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors	NCT00499798	Brain and Centr... Chemotherapeuti... Infertility		18 Years - 60 Years	Wake Forest University Health Sciences
Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors	NCT00008086	Brain and Centr... Unspecified Adu...	calcitriol carboplatin	18 Years -	University of Pittsburgh
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors	NCT00002647	Brain and Centr... Metastatic Canc...	verteporfin conventional su...	3 Years - 70 Years	National Cancer Institute (NCI)
Vatalanib in Treating Patients With Recurrent or Progressive Meningioma	NCT00348790	Brain and Centr... Sarcoma	vatalanib	18 Years -	Northwestern University
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors	NCT00003461	Brain and Centr... Metastatic Canc... Neuroblastoma	surgical proced... astatine At 211...	18 Years -	Duke University
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma	NCT00010049	Brain and Centr...	imatinib mesyla...	18 Years - 120 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor	NCT00070161	Brain and Centr... Radiation Toxic...	EGb761 donepezil hydro... cognitive asses...	18 Years - 120 Years	Wake Forest University Health Sciences
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors	NCT00003461	Brain and Centr... Metastatic Canc... Neuroblastoma	surgical proced... astatine At 211...	18 Years -	Duke University
Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma	NCT00006119	Brain and Centr...	hydroxyurea	16 Years - 120 Years	UNICANCER
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2	NCT01082926	Anaplastic Astr... Anaplastic Epen... Anaplastic Meni... Anaplastic Olig... Brain Stem Glio... Ependymoblastom... Giant Cell Glio... Glioblastoma Gliosarcoma Grade III Menin... Meningeal Heman... Mixed Glioma Pineal Gland As... Brain Tumor	therapeutic all... aldesleukin laboratory biom... positron emissi...	18 Years - 70 Years	City of Hope Medical Center
Radiation Therapy in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Grade II or Grade III Meningioma	NCT00626730	Brain and Centr...	adjuvant therap... radiation thera...	18 Years - 70 Years	European Organisation for Research and Treatment of Cancer - EORTC
Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors	NCT00110032	Adult Anaplasti... Adult Anaplasti... Adult Anaplasti... Adult Brain Ste... Adult Central N... Adult Choroid P... Adult Craniopha... Adult Diffuse A... Adult Ependymob... Adult Ependymom... Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Adult Grade I M... Adult Grade II ... Adult Grade III... Adult Medullobl... Adult Meningeal... Adult Mixed Gli... Adult Myxopapil... Adult Oligodend... Adult Pilocytic... Adult Pineoblas... Adult Pineocyto... Adult Subependy... Adult Supratent... Meningeal Melan...	EF5 conventional su... positron emissi... fluorine F 18 E... pharmacological...	18 Years -	National Cancer Institute (NCI)
Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma	NCT00895622	Brain and Centr...	54 Gy radiother... 60 Gy radiother...	18 Years -	Radiation Therapy Oncology Group
CC-5013 in Treating Patients With Recurrent Glioma	NCT00036894	Brain and Centr...	lenalidomide	18 Years -	National Cancer Institute (NCI)
Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors	NCT00008086	Brain and Centr... Unspecified Adu...	calcitriol carboplatin	18 Years -	University of Pittsburgh
Vatalanib in Treating Patients With Recurrent or Progressive Meningioma	NCT00348790	Brain and Centr... Sarcoma	vatalanib	18 Years -	Northwestern University
Stress Reduction Program in Patients With Malignant Brain Tumors and Their Family Caregivers	NCT00376818	Brain and Centr... Psychosocial Ef...	exercise interv... educational int... physiologic tes... management of t... mind-body inter... Measurement of ...	18 Years -	Case Comprehensive Cancer Center
Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders	NCT00255671	Brain and Centr... Metastatic Canc... Radiation Toxic...	Questionnaire	18 Years -	Case Comprehensive Cancer Center
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors	NCT00025675	Brain and Centr...	gefitinib	18 Years - 120 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Imatinib Mesylate in Treating Patients With Recurrent Meningioma	NCT00045734	Adult Grade I M... Adult Grade II ... Adult Grade III... Adult Meningeal... Adult Meningiom... Recurrent Adult...	imatinib mesyla... laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer	NCT00014573	Brain and Centr...	aldesleukin autologous tumo... filgrastim sargramostim therapeutic aut... carmustine cisplatin cyclophosphamid... paclitaxel autologous bone... conventional su... peripheral bloo...	- 65 Years	Barbara Ann Karmanos Cancer Institute
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer	NCT00006368	Brain and Centr... Breast Cancer Gastrointestina... Islet Cell Tumo... Lung Cancer Lymphoma Melanoma (Skin) Neoplastic Synd...	yttrium Y 90-ed...	18 Years -	Novartis
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment	NCT00544284	Brain and Centr... Lymphoma Metastatic Canc... Unspecified Adu...	bortezomib temozolomide pharmacological...	18 Years -	City of Hope Medical Center
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma	NCT00010049	Brain and Centr...	imatinib mesyla...	18 Years - 120 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer	NCT00492089	Adult Anaplasti... Adult Anaplasti... Adult Anaplasti... Adult Anaplasti... Adult Brain Ste... Adult Central N... Adult Choroid P... Adult Diffuse A... Adult Ependymom... Adult Grade II ... Adult Grade III... Adult Malignant... Adult Mixed Gli... Adult Oligodend... Adult Papillary... Adult Pineocyto... Malignant Neopl... Meningeal Melan... Radiation Toxic... Recurrent Adeno... Recurrent Adult... Recurrent Basal... Recurrent Esthe... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Midli... Recurrent Mucoe... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage I Adenoid... Stage I Basal C... Stage I Esthesi... Stage I Inverte... Stage I Lymphoe... Stage I Lymphoe... Stage I Midline... Stage I Mucoepi... Stage I Salivar... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Verruco... Stage I Verruco... Stage III Adeno... Stage III Basal... Stage III Esthe... Stage III Inver... Stage III Lymph... Stage III Midli... Stage III Mucoe... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Adenoi... Stage IV Basal ... Stage IV Esthes... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc...	bevacizumab placebo magnetic resona... quality-of-life...	18 Years -	National Cancer Institute (NCI)
Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma	NCT00354913	Glioblastoma Gliosarcoma	hydroxyurea imatinib mesyla...	18 Years -	Duke University
Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma	NCT00895622	Brain and Centr...	54 Gy radiother... 60 Gy radiother...	18 Years -	Radiation Therapy Oncology Group
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer	NCT00492089	Adult Anaplasti... Adult Anaplasti... Adult Anaplasti... Adult Anaplasti... Adult Brain Ste... Adult Central N... Adult Choroid P... Adult Diffuse A... Adult Ependymom... Adult Grade II ... Adult Grade III... Adult Malignant... Adult Mixed Gli... Adult Oligodend... Adult Papillary... Adult Pineocyto... Malignant Neopl... Meningeal Melan... Radiation Toxic... Recurrent Adeno... Recurrent Adult... Recurrent Basal... Recurrent Esthe... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Midli... Recurrent Mucoe... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage I Adenoid... Stage I Basal C... Stage I Esthesi... Stage I Inverte... Stage I Lymphoe... Stage I Lymphoe... Stage I Midline... Stage I Mucoepi... Stage I Salivar... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Verruco... Stage I Verruco... Stage III Adeno... Stage III Basal... Stage III Esthe... Stage III Inver... Stage III Lymph... Stage III Midli... Stage III Mucoe... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Adenoi... Stage IV Basal ... Stage IV Esthes... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc...	bevacizumab placebo magnetic resona... quality-of-life...	18 Years -	National Cancer Institute (NCI)
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors	NCT00003484	Brain and Centr... Neuroblastoma	carmustine irinotecan hydr... surgical proced... iodine I 131 mo...	18 Years -	Duke University

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: